S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
Log in
OTCMKTS:ENZN

Enzon Pharmaceuticals Short Interest Ratio and Short Volume

$0.59
-0.02 (-3.27 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.53
Now: $0.59
$0.62
50-Day Range
$0.30
MA: $0.52
$0.84
52-Week Range
$0.02
Now: $0.59
$0.85
Volume248,867 shs
Average Volume432,643 shs
Market Capitalization$43.97 million
P/E RatioN/A
Dividend YieldN/A
Beta0.77

Short Interest

Enzon Pharmaceuticals (OTCMKTS:ENZN) Short Interest Data

Current Short Volume44,400 shares
Previous Short Volume36,500 shares
Change Vs. Previous Month:+21.64%
Dollar Volume Sold Short$19,536.00
Short Interest Ratio / Days to Cover0.0
Last Record DateJanuary, 29 2021
Outstanding Shares74,215,000 shares
Percentage of Shares Shorted0.06%
Today's Trading Volume248,867 shares
Average Trading Volume432,643 shares
Today's Volume Vs. Average-42.48%

Short Interest Over Time


Enzon Pharmaceuticals (OTCMKTS:ENZN) Short Interest History

Report DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date
1/29/202144,400 shares $19,536.00 +21.6%N/A0.1 $0.44
1/15/202143,700 shares $13,765.50 +241.4%N/A0.1 $0.32
12/31/202043,700 shares $11,750.93 +241.4%N/A0.1 $0.27
12/15/202043,700 shares $10,925.00 +241.4%N/A0.1 $0.25
11/30/202012,800 shares $3,200.00 -36.6%N/A0.1 $0.25
11/15/202020,200 shares $3,434.00 +5.8%N/A0.2 $0.17
10/30/202019,100 shares $2,865.00 +135.8%N/A0.2 $0.15
10/15/20208,100 shares $1,297.62 +88.4%N/A0 $0.16
9/30/20204,300 shares $796.36 -62.0%N/A0.1 $0.19
9/15/202011,300 shares $2,147.00 -29.8%N/A0.1 $0.19
8/31/202016,100 shares $3,052.56 -53.9%N/A0.1 $0.19
8/14/202034,900 shares $7,503.50 +122.3%N/A0.1 $0.22
7/31/202015,700 shares $3,140.00 -38.2%N/A0.3 $0.20
7/15/202025,400 shares $5,080.00 +103.2%N/A0.8 $0.20
6/30/202012,500 shares $2,180.00 -30.2%N/A0.8 $0.17
6/15/202017,900 shares $2,864.00 -67.7%N/A0.5 $0.16
5/29/202055,400 shares $9,418.00 +32.2%N/A3 $0.17
5/15/202041,900 shares $7,542.00 -31.7%N/A0.9 $0.18
4/30/202061,300 shares $11,003.35 +656.8%N/A0.8 $0.18
4/15/20208,100 shares $1,263.60 -80.9%N/A0 $0.16
3/31/202042,500 shares $6,800.00 +962.5%N/A0.3 $0.16
3/13/20204,000 shares $640.00 +66.7%N/A0.1 $0.16
2/28/20202,400 shares $444.00 -40.0%N/A0 $0.19
2/14/20204,000 shares $680.00 -9.1%N/A0.1 $0.17
1/31/20204,400 shares $924.00 No ChangeN/A0.2 $0.21

Enzon Pharmaceuticals (OTCMKTS:ENZN) Short Interest FAQ

speech bubbles
speech bubbles











What is Enzon Pharmaceuticals' current short interest?

Short interest is the volume of Enzon Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of January 29th, traders have sold 44,400 shares of ENZN short.

Is Enzon Pharmaceuticals' short interest increasing or decreasing?

Enzon Pharmaceuticals saw a increase in short interest in January. As of January 29th, there was short interest totaling 44,400 shares, an increase of 21.6% from the previous total of 36,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Enzon Pharmaceuticals' short interest compare to its competitors?

0.00% of Enzon Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sub-industry of "biotechnology" compare to Enzon Pharmaceuticals: Amgen Inc. (1.31%), Gilead Sciences, Inc. (1.73%), Vertex Pharmaceuticals Incorporated (0.00%), Regeneron Pharmaceuticals, Inc. (1.90%), Biogen Inc. (2.41%), Alexion Pharmaceuticals, Inc. (2.00%), Seagen Inc. (0.00%), Exact Sciences Co. (0.00%), Alnylam Pharmaceuticals, Inc. (0.00%), and Incyte Co. (0.00%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Aon Plc ($5.34 billion), Charter Communications, Inc. ($5.03 billion), ViacomCBS Inc. ($4.99 billion), DuPont de Nemours, Inc. ($4.72 billion), Analog Devices, Inc. ($4.57 billion), Snap Inc. ($3.87 billion), Moderna, Inc. ($3.58 billion), Futu Holdings Limited ($2.75 billion), Snowflake Inc. ($2.43 billion), and Palantir Technologies Inc. ($2.18 billion). View all of the most shorted stocks.

What does it mean to sell short Enzon Pharmaceuticals stock?

Short selling ENZN is an investing strategy that aims to generate trading profit from Enzon Pharmaceuticals as its price is falling. Enzon Pharmaceuticals' stock is trading down $0.02 today. To short Enzon Pharmaceuticals stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Enzon Pharmaceuticals will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Enzon Pharmaceuticals?

A short squeeze for Enzon Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ENZN, which in turn drives the price of the stock up even further.

How often is Enzon Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ENZN, twice per month. The most recent reporting period available is January, 29 2021.



This page was last updated on 2/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.